

MEME KARSİNOMUNDA MOLEKÜLER GÖRÜNTÜLEME VE RADYO-İŞARETLEME PROSEDÜRLERİ

Pınar Pelin ÖZCAN¹
Zehra Pınar KOÇ²
Zeynep Selcan SAĞLAM³

GİRİŞ

Meme kanseri kadınlarda en sık görülen kanserdir. Kanserden ölüm nedenleri arasında ikinci sıradadır. Nükleer Tıp bölümünde rutin olarak yapılan sentinel lenf nodu (SLN), radyasyon kılavuzluğunda okült lezyon (ROLL) uygulamaları, primer tanı, evreleme, yeniden evreleme ve tedavi yanıt amaçlı yapılan florodeoksiglukoz pozitron emisyon tomografisi-bilgisayarlı tomografi (FDG-PET-BT) görüntülemeleri erken ve ileri evre meme kanserli hastalarda oldukça önem arz etmektedir. Bu bölümde meme kanserli hastalarda Nükleer Tıp uygulamaları ayrıntılı olarak anlatılacaktır.

MEME KANSERİNDE PRİMER TÜMÖR VE SENTİNEL LENF NODU GÖRÜNTÜLEME

SENTİNEL LENF NODU GÖRÜNTÜLEME, LENFATİK HARİTALAMA VE ROLL

Kanser yayılımında en önemli yollardan biri lenfatik yayılımdır. Kanserli hücreler yerleştiği bölgeye bağlı olarak ilk planda bölgesel lenf nodlarına ilerler ve bu lenf bezlerine mikrometastaz

yaparlar. Sentinel lenf nodu (SLN) tümörün ilk drene olduğu lenf nodu olup, tüm lenfatik yatağın histopatolojisini yansıtmaktadır. SLN konsepti, tümör hücrelerinin primer tümörden 'sentinel nod' denilen ilk lenf noduna ve daha sonra belirli bir sıra ile diğer lenf nodlarına yayılması teorisine dayanır. Dolayısıyla SLN'nin histopatolojisi, tümörün yayılma olasılığı bulunan tüm lenfatik yatağın histopatolojisini yansıtmaktadır. SLN metastaz içermiyorsa, lenfatik yatakta bulunan diğer lenf nodları da metastaz açısından negatif olacaktır. Diğer taraftan sentinel nod metastaz açısından pozitif bulunursa, diğer lenf nodlarında metastaz bulunma olasılığı yüksek olacaktır. Birden fazla lenf nodu bulunduğu durumlarda her ikisinin de SLN olup olmadığı, aksi takdirde bir lenf nodu gerçek SLN iken diğer lenf nodunun 'second echelon' olup olmadığıdır. Second echelon lenf nodu, lenfatik drenajını primer tümör yerine SLN'den alan lenf nodudur. Bu gibi durumlarda mavi boya renginin yoğunluğu SLN ve second echelon ayrımı yaptıramaz, radyoaktif sayıma bakılabilir ancak sentinel nod için hangi kriterin kullanılacağı tartışma konusudur. Arada kalındığı zaman her

¹ Prof.Dr., Nükleer Tıp Anabilim Dalı, Mersin Üniversitesi Hastanesi, ppelinozcan@gmail.com

² Prof.Dr., Nükleer Tıp Anabilim Dalı, Mersin Üniversitesi Hastanesi, zehrapinarkoc@gmail.com

³ Arş.Gör.Dr., Nükleer Tıp Anabilim Dalı, Mersin Üniversitesi Hastanesi, z.selcansaglam@gmail.com

KAYNAKÇA

- Gould EA, Winship T, Philbin PH, Hyland Kerr H. Observations on a 'sentinel node' in cancer of the parotid. *Cancer* 1960;13:77-8.
- Cabanas RM. An approach for the treatment of penile carcinoma. *Cancer* 1977;39:456-466.
- Abdollahi A, Jangjoo A, Dabbagh Kakhki VR, et al. Factors affecting sentinel lymph node detection failure in breast cancer patients using intradermal injection of the tracer. *Rev Esp Med Nucl* 2010;29:73-77.
- Wilhelm AJ, Mijnhout GS, Franssen EJ. Radiopharmaceuticals in sentinel lymph node detection-an overview. *Eur J Nucl Med* 1999; 26 (4 Suppl 9): S36-42.
- Glass EC, Esner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. *J Nucl Med* 1998; 39: 1185-1190.
- Morton DL, Wen DR, Wong JH et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. *Arch Surg* 1992;127:392-399.
- Zanzonico P, Heller S. The intraoperative gamma probe: Basic principles and choices available. *Semin Nucl Med* 2000; 30:33-48.
- Alexander CW, Hazel Gore, Hugh M. Shingleton, James A. Wilkerson, Seng Jaw Soong, Kenneth D. Hatch. Lymph node metastasis in cancer of the cervix: A preliminary report. *Am J Obstet Gynecol* 1986;155:388-9.
- Van Diest Paul J, Peterse Hans L, Borgstein Paul J, Hoekstra Otto, Meijer Chris J.L.M. Pathological investigation of sentinel lymph nodes. *Eur J Nucl Med* 1999; 26 (Suppl): S43-S49.
- Gershenwald JE, Colome MI, Lee JE et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. *J Clin Oncol* 1998;16:2253-2260.
- Miner TJ, Shriver CD, Flicek PR, et. al. Guidelines for the safe use of radioactive materials during localization and resection of the sentinel lymph node. *Ann Surg Oncol*. 1999 Jan-Feb;6(1):75-82.
- Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. *J Natl Cancer Inst* 1999; 91: 368-373.
- Klausen TL, Chakera AH, Friis E, Rank F, Hesse B, Holm S. Radiation doses to staff involved in sentinel node operations for breast cancer. *Clin Physiol Funct Imaging* 2005;25:196-202.
- Glass EC, Basinski JE, Krasne DL, Giuliano AE. Radiation safety considerations for sentinel node techniques. *Ann Surg Oncol* 1999;6:10-11.
- Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. *J Nucl Med* 2006;47:1202-1208.
- Giammarile F, Alazraki N, Aarsvold JN, et al. The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. *Eur J Nucl Med Mol Imaging* 2013;40:1932-1947.
- Ugur O, Bozkurt MF, Sayek İ, et.al. Comparison of blue dye and gamma probe guided sentinel lymph node biopsy techniques in breast cancer patients. *Turk J Cancer* 2003; 33:82-90.
- Nieweg OE, Estourgie SH, van Rijk MC, Kroon BB. Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients. *J Surg Oncol* 2004;87:153-156.
- Hindié E, Groheux D, Espie M, et al. [Sentinel node biopsy in breast cancer]. *Bull Cancer* 2009;96:713-725.
- Garbay JR, Skalli-Chrisostome D, Leymarie N, et al. The Role of Blue Dye in Sentinel Node Detection for Breast Cancer: A Retrospective Study of 203 Patients. *Breast Care (Basel)* 2016;11:128-132.
- Van Der Ploeg IM, Nieweng OE, Kroon BB et.al. The yield of SPECT/CT for anatomical lymphatic mapping in patients with breast cancer. *Eur J Nucl Med Mol imaging* 2009;36:903-909.
- Husarik DB, Steinert HC. Single-photon emission computed tomography/ computed tomography for sentinel node mapping in breast cancer. *Semin Nucl Med* 2007;37:29-33.
- Lerman H, Metser U, Liovshitz G, Sperber F, Shneebaum S, Even-Sapir E. Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT. *Eur J Nucl Med Mol Imaging* 2006;33:329-337.
- Mucientes Rasilla J, Farge Balbin L, Cardona Arbories J, et al. SPECT-CT: a new tool for localisation of sentinel lymph nodes in breast cancer patients. *Rev Esp Med Nucl* 2008;27:183-190.
- Lerman H, Liovshitz G, Zak O, Metser U, Schneebaum S, Even- Sapir E. Improved sentinel node identification by SPECT/ CT in overweight patients with breast cancer. *J Nucl Med* 2007;48:201-206.
- Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: Use and limitations. *Journal of Clinical Oncology*.2000;18:3495-3502.
- Avril N, Menzel M, Dose J, et al. Glucose metabolism of breast cancer assessed by F-18 FDG PET: Histologic and immunohistochemical tissue analysis. *Journal of Nuclear Medicine*.2001;42.9-16.

28. Buck A, Schirrmester H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. *European Journal of Nuclear Medicine and Molecular Imaging*. 2002;29:1317-1323.
29. Samson DJ, Flamm CR, Pisano ED, Aronson N. Should FDG PET be used to decide whether a patient with an abnormal mammogram or breast finding at physical examination should undergo biopsy? *Academic Radiology*. 2003;13:1651-1656.
30. Moses WW. Positron emission mammography imaging. *Nuclear Instruments & Methods in Physics Research Section a-Accelerators Spectrometers detectors and Associated Equipment*. 2004;525:249-252.
31. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression ('positron emission tomography') is highly accurate in depicting primary breast cancer. *Breast Journal*. 2006;12:309-323.
32. Eo JS, Chun IK, Paeng JC, et al. Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. *Berast*. 2012;21:66-71.
33. Garg PK, Deo SV, Kumar R. Role of Positron Emission Tomography-Computed Tomography in Locally Advanced Breast Cancer. *Indian J Surg Oncol*. 2015 Dec;6(4):420-6.
34. Cancer Staging [Internet]. National Cancer Institute. [cited 2015 Apr 12]. Available from: <http://www.cancer.gov/cancertopics/diagnosis-staging/staging/staging-fact-sheet>.
35. NCCN clinical practice guidelines in oncology (NCCN guidelines®) Breast Cancer, Version 2.2015 [Internet]. [cited 2015 May 10]. Available from: http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
36. Ben-Haim S, Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. *Semin Nucl Med*. 2009 Nov;39(6):408-15.
37. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. *J Clin Oncol* 22:2924-2953, 2005
38. Schirrmester H: Detection of bone metastases in breast cancer by positron emission tomography. *Radiol Clin North Am* 45:669-676, 2007
39. Mortimer JE, Dehdashti F, Siegel BA: Metabolic flare: Indicator of hormone responsiveness in advanced breast cancer. *J Clin Oncol* 19:2797-2803, 2001
40. Even-Sapir E: Imaging of malignant bone involvement by morphologic, scintigraphic and hybrid modalities. *J Nucl Med* 46:1356-1367, 2005
41. Kosuda S, Kaji T, Yokohama H, et al. Does bone SPECT actually have lower sensitivity for detecting vertebral metastasis than MRI? *J Nucl Med* 37:975-978, 1996
42. Ary O Pires , Umbelina S Borges , Pedro V Lopes-Costa , Luiz H Gebrim , Benedito B da Silva : Evaluation of bone metastases from breast cancer by bone scintigraphy and positron emission tomography/computed tomography imaging *Eur J Obstet Gynecol Reprod Biol* 2014 Sep;180:138-41.
43. Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. *Ann Oncol* 2012;23:834-43.
44. Iagaru A, Minamimoto R. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. *PET Clin*. 2018 Jul;13(3):383-393.
45. Fogelman I, Gnanasegaran G, Wall HVD. Radionuclide and hybrid bone imaging. New York: Springer 2013; p. 635-89.
46. Sharma P, Singh H, Kumar R, et al. Bone scintigraphy in breast cancer: added value of hybrid SPECT-CT and its impact on patient management. *Nucl Med Commun* 2012;33:139-47.
47. Eleni Mavriopoulou , Petros Zampakis, Evaggelia Smpiliri, et al. Whole body bone SPET/CT can successfully replace the conventional bone scan in breast cancer patients. A prospective study of 257 patients. *Hell J Nucl Med* 2018;21(2):125-133.
48. Rosselli Del Turco M, Palli D, Cariddi A, et al. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. National Research Council Project on Breast Cancer follow-up. *JAMA* 1994;271:1593-7.
49. Erdi YE, Humm JL, Imbriaco M, et al. Quantitative bone metastases analysis based on image segmentation. *J Nucl Med* 1997;38:1401-6.
50. Iwase T, Yamamoto N, Ichihara H, et al. The relationship between skeletal-related events and bone scan index for the treatment of bone metastasis with breast cancer patients. *Medicine (Baltimore)* 2014;93:e269.
51. Domchek SM, Younger J, Finkelstein DM, Seiden MV. Predictors of skeletal complications in patients with metastatic breast carcinoma. *Cancer* 2000; 89: 363-8.
52. Koizumi M, Yoshimoto M, Kasumi F, Ogata E. What do breast cancer patients benefit from staging bone scintigraphy? *Jpn J Clin Oncol*. 2001 Jun;31(6):263-9.
53. Teke F, Teke M, Inal A, ve ark. Significance of hormone receptor status in comparison of 18F-FDG-PET/CT and 99mTc-MDP bone scintigraphy for evaluating bone metastases in patients with breast cancer: single center experience. *Asian Pac J Cancer Prev*. 2015;16(1):387-91.

54. Begić A, Kucukalić-Selimović E, Obralić N, Durić O, Lacević N, Skopljak A. Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma. *Bosn J Basic Med Sci.* 2006 Feb;6(1):75-7.
55. Damle NA, BalC, BandopadhyayaGP, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: A comparison with FDG-PET/CT and 99mTc-MDP bone scan. *JpnJRadiol* 2013;31(4):262-269
56. Kevin J Donohoe, Erica J Cohen, Francesco Giammarile, et al. Appropriate Use Criteria for Bone Scintigraphy in Prostate and Breast Cancer: Summary and Excerpts *J Nucl Med.* 2017 Apr;58(4):14N-17N.
57. Andreas Gutzeit, Aleksis Doert, Johannes M Froehlich, et al. Comparison of diffusion-weighted whole body MRI and skeletal scintigraphy for the detection of bone metastases in patients with prostate or breast carcinoma. *Skeletal Radiol.* 2010 Apr;39(4):333-43.
58. Inaki A, Nakajima K, Wakabayashi H, Mochizuki T, Kinuya S. Fully automated analysis for bone scintigraphy with artificial neural network: usefulness of bone scan index (BSI) in breast cancer. *Ann Nucl Med.* 2019 Oct;33(10):755-765.
59. Cook GJ, Azad GK, Goh V. Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. *J Nucl Med.* 2016 Feb;57 Suppl 1:27S-33S.
60. Morris PG, Lynch C, Feeney JN, et al. Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer. *J Clin Oncol.* 2010 Jul 1;28(19):3154-9.
61. Niikura N, Hashimoto J, Kazama T, et al. Diagnostic performance of (18)F-fluorodeoxyglucose PET/CT and bone scintigraphy in breast cancer patients with suspected bone metastasis. *Breast Cancer.* 2016 Jul;23(4):662-7.
62. Jambor I, Kuisma A, Kähkönen E, et al. Prospective evaluation of (18)F-FACBC PET/CT and PET/MRI versus multiparametric MRI in intermediate- to high-risk prostate cancer patients (FLUCIPRO trial). *Eur J Nucl Med Mol Imaging.* 2018 Mar;45(3):355-364.
63. Riaz S, Bashir H, Hassan A, Nawaz MK. Musculoskeletal Spect-Ct: A Pictorial Review. *J Ayub Med Coll Abbottabad.* 2016 Apr-Jun;28(2):427-437.
64. Rong J, Wang S, Ding Q, Yun M, Zheng Z, Ye S. Comparison of 18 FDG PET-CT and bone scintigraphy for detection of bone metastases in breast cancer patients. A meta-analysis. *Surg Oncol.* 2013 Jun;22(2):86-91.
65. Al-Muqbel KM, Yaghan RJ. Value of baseline and follow-up whole-body bone scans in detecting bone metastasis in high-risk breast cancer patients. *Nucl Med Commun.* 2013 Jun;34(6):577-81.
66. Abikhzer G, Gourevich K, Kagna O, Israel O, Frenkel A, Keidar Z. Whole-body bone SPECT in breast cancer patients: the future bone scan protocol? *Nucl Med Commun.* 2016 Mar;37(3):247-53.
67. Claire Tabouret-Viaud, Diomidis Botsikas, Bénédicte M A Delattre, et al. PET/MR in Breast Cancer *Semin Nucl Med.* 2015 Jul;45(4):304-21.
68. Groheux D, Moretti JL, Baillet G, et al. Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. *Int J Radiat Oncol Biol Phys* 2008;71(3):695-704
69. Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014. *J Natl Compr Canc Netw* 2014;12(4):542-590
70. Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications. *Radiology* 2013;267(1):26-44
71. Taneja S, Jena A, Goel R, et al. Simultaneous whole-body F-FDG PET-MRI in primary staging of breast cancer: A pilot study. *Eur J Radiol* 2014;83:2231-2239
72. Huynh PT, Lemeshko SV, Mahoney MC, et al. ACR Appropriateness Criteria() Stage I Breast Carcinoma. *J Am Coll Radiol.* 2016 Nov;13(11S):e53-e57.
73. Jain S, Fisher C, Smith P, Millis RR, Rubens RD. Patterns of metastatic breast cancer in relation to histological type. *Eur J Cancer* 1993;29A:2155-7.
74. Chakraborty D, Basu S, Ulaner GA, Alavi A, Kumar R. Diagnostic Role of Fluorodeoxyglucose PET in Breast Cancer: A History to Current Application. *PET Clin.* 2018 Jul;13(3):355-361.
75. Dashevsky BZ, Goldman DA, Parsons M, et al. Appearance of untreated bone metastases from breast cancer on FDGPET/CT: importance of histologic subtype. *Eur J Nucl Med Mol Imaging* 2015;42(11):1666-73.
76. Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. *Cancer* 2008;112(5):995-1000.
77. Buck A, Schirrmeyer H, Kuhn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. *Eur J Nucl Med Mol Imaging* 2002;29:1317-23.

78. Cooper KL, Harnan S, Meng Y, et al. Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. *Eur J Surg Oncol* 2011;37:187–98.
79. Groheux D, Giacchetti S, Delord M, et al. 18 F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. *J Nucl Med* 2013;54:5–11.
80. Ravina M, Saboury B, Chauhan MS, et al. Utility of (18) F-FDG PET/CT in pre-surgical risk stratification of patients with breast cancer. *Hell J Nucl Med*. 2019 Sep-Dec;22(3):165-171.
81. Hildebrandt MG, Gerke O, Baun C et al. F-Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) in Suspected Recurrent Breast Cancer: A Prospective Comparative Study of Dual-Time-Point FDG-PET/CT, Contrast-Enhanced CT, and Bone Scintigraphy. *J Clin Oncol* 2016; 34: 1889-97.
82. Ozkan EE, Sengul SS, Erdogan M, Gurdal O, Ergolu HE. 18F-fluorodeoxyglucose PET/computed tomography in locoregional staging and assessment of biological and clinical aggressiveness of breast cancer subtypes. *Nucl Med Commun*. 2019 Oct;40(10):1043-1050.
83. Ana Paula Caresia Aroztegui , Ana María García Vicente , Soledad Alvarez Ruiz , et al. 18F-FDG PET/CT in breast cancer: Evidence-based recommendations in initial staging. *Tumour Biol*. 2017 Oct;39(10):1010428317728285.
84. Ulaner GA. PET/CT for Patients With Breast Cancer: Where Is the Clinical Impact? *AJR Am J Roentgenol*. 2019 Aug;213(2):254-265.
85. Sormani MP. The Will Rogers phenomenon: the effect of different diagnostic criteria. *J Neurol Sci* 2009; 287(suppl 1):S46–S49
86. Yararbas U, Cetin Avci N, Yeniay L, Argon AM. The value of 18F-FDG PET/CT imaging in breast cancer staging *Bosn J Basic Med Sci*. 2018 Feb 20;18(1):72-79.
87. Shie P, Cardarelli R, Brandon D, Erdman W, Abdulrahim N. Meta-analysis: Comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer. *Clin Nucl Med* 2008;33(2):97-101.
88. Diomidis Botsikas , Anastasia Kalovidouri , Minerva Becker et al. Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging *Eur Radiol*. 2016 Jul;26(7):2297-307.
89. Pace L, Nicolai E, Luongo A et al. (2014) Comparison of wholebody PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. *Eur J Radiol* 83:289–296
90. Diomidis Botsikas , Ilias Bagetakos , Marlise Picarra , et al. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer? *Eur Radiol*. 2019 Apr;29(4):1787-1798.
91. Baltzer PA, Dietzel M, Burmeister HP, et al. (2011) Application of MR mammography beyond local staging: is there a potential to accurately assess axillary lymph nodes? evaluation of an extended protocol in an initial prospective study. *Am J Roentgenol* 196: W641–W647
92. Park HL, Yoo IR, O JH, Kim H, Kim SH, Kang BJ. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI. *Nucl Med Commun*. 2018 Jan;39(1):35-43.
93. Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. 18F-FDG PET/CT for Staging and Restaging of Breast Cancer. *J Nucl Med*. 2016 Feb;57 Suppl 1:17S-26S.
94. Paydary K, Seraj SM, Zadeh MZ, et al. The Evolving Role of FDG-PET/CT in the Diagnosis, Staging, and Treatment of Breast Cancer. *Mol Imaging Biol*. 2019 Feb;21(1):1-10.
95. Arslan E, Çermik TF, Trabulus FDC, Talu ECK, Başaran Ş. Role of 18F-FDG PET/CT in evaluating molecular subtypes and clinicopathological features of primary breast cancer. *Nucl Med Commun*. 2018 Jul;39(7):680-690.
96. Ulaner GA, Castillo R, Goldman DA, et al. (18) F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer. *Eur J Nucl Med Mol Imaging*. 2016 Oct;43(11):1937-44.
97. Ulaner GA, Castillo R, Wills J, Gönen M, Goldman DA. (18)F-FDG-PET/CT for systemic staging of patients with newly diagnosed ER-positive and HER2-positive breast cancer. *Eur J Nucl Med Mol Imaging*. 2017 Aug;44(9):1420-1427.
98. Ulaner GA, Juarez J, Riedl CC, Goldman DA. (18) F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer in Men. *J Nucl Med*. 2019 Apr;60(4):472-477.
99. Rugo HS, Rumble RB, Macrae E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. *J Clin Oncol* 2016;34: 3069–3103.
100. Liu C, Gong C, Liu S, et al. (18)F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with (18)F-FDG PET/CT. *Oncologist*. 2019 Dec;24(12):e1277-e1285.
101. Broos WAM, van der Zant FM, Wondergem M, Knol RJJ. Accuracy of 18F-NaF PET/CT in bone metastasis detection and its effect on patient ma

- nagement in patients with breast carcinoma. *Nucl Med Commun.* 2018 Apr;39(4):325-333.
102. Hillner BE, Siegel BA, Hanna L, Duan F, Quinn B, Shields AF. 18F-fluoride PET used for treatment monitoring of systemic cancer therapy: results from the National Oncologic PET Registry. *J Nucl Med* 2015; 56:222–228.
103. Goorts B, Vöö S, van Nijnatten TJA, et al. Hybrid (18)F-FDG PET/MRI might improve loco-regional staging of breast cancer patients prior to neoadjuvant chemotherapy. *Eur J Nucl Med Mol Imaging.* 2017 Oct;44(11):1796-1805.
104. van der Noordaa MEM, van Duijnhoven FH, Straver ME, et al. Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure. *Ann Surg Oncol.* 2018 Jun;25(6):1512-1520.
105. Yoo J, Kim BS, Yoon HJ. Predictive value of primary tumor parameters using (18)F-FDG PET/CT for occult lymph node metastasis in breast cancer with clinically negative axillary lymph node. *Ann Nucl Med.* 2018 Nov;32(9):642-648.
106. Quintela-Fandino M, Lluch A, Manso L, et al. (18)F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. *Clin Cancer Res.* 2017 Mar 15;23(6):1432-1441.
107. Andrzejewski P, Wengert G, Helbich TH, et al. Sequential [(18)F]FDG-[(18)F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience. *Contrast Media Mol Imaging.* 2019 Jan 8;2019:1307247.